Cornerstone Capital Management Holdings LLC. trimmed its holdings in bluebird bio, Inc. (NASDAQ:BLUE) by 6.1% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 16,855 shares of the biotechnology company’s stock after selling 1,100 shares during the quarter. Cornerstone Capital Management Holdings LLC.’s holdings in bluebird bio were worth $2,314,000 at the end of the most recent quarter.
Several other institutional investors have also added to or reduced their stakes in the stock. Nicholas Investment Partners LP increased its stake in shares of bluebird bio by 42.1% in the 3rd quarter. Nicholas Investment Partners LP now owns 71,329 shares of the biotechnology company’s stock valued at $9,797,000 after acquiring an additional 21,146 shares during the last quarter. Stifel Financial Corp bought a new stake in shares of bluebird bio in the 3rd quarter valued at about $391,000. Dimensional Fund Advisors LP grew its position in shares of bluebird bio by 31.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 139,994 shares of the biotechnology company’s stock valued at $19,231,000 after purchasing an additional 33,805 shares during the period. Schwab Charles Investment Management Inc. grew its position in shares of bluebird bio by 51.9% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 266,693 shares of the biotechnology company’s stock valued at $36,631,000 after purchasing an additional 91,161 shares during the period. Finally, Mckinley Capital Management LLC Delaware acquired a new position in shares of bluebird bio in the 3rd quarter valued at approximately $292,000.
Several equities analysts recently issued reports on the company. Wells Fargo & Co reiterated an “outperform” rating and issued a $242.00 price objective (up from $190.00) on shares of bluebird bio in a research report on Tuesday, December 12th. SunTrust Banks boosted their price objective on bluebird bio to $223.00 and gave the company a “buy” rating in a research report on Tuesday, December 12th. Barclays reaffirmed an “overweight” rating and set a $209.00 price target (up previously from $162.00) on shares of bluebird bio in a research report on Wednesday, December 13th. Maxim Group downgraded bluebird bio from a “buy” rating to a “hold” rating and set a $200.00 price target for the company. in a research report on Wednesday, December 13th. They noted that the move was a valuation call. Finally, CIBC began coverage on bluebird bio in a research report on Thursday, December 21st. They set a “market perform” rating for the company. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and thirteen have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $157.45.
bluebird bio, Inc. (NASDAQ:BLUE) traded down $0.30 during mid-day trading on Thursday, reaching $171.65. The company’s stock had a trading volume of 424,502 shares, compared to its average volume of 623,733. The company has a market cap of $7,870.00, a PE ratio of -24.49 and a beta of 2.08. bluebird bio, Inc. has a 1 year low of $63.10 and a 1 year high of $222.03.
bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the consensus estimate of ($1.68) by ($0.05). The firm had revenue of $7.71 million for the quarter, compared to the consensus estimate of $8.47 million. bluebird bio had a negative return on equity of 28.79% and a negative net margin of 883.18%. The firm’s quarterly revenue was up 397.4% on a year-over-year basis. During the same quarter in the previous year, the business earned ($2.07) EPS. sell-side analysts predict that bluebird bio, Inc. will post -6.72 earnings per share for the current year.
In related news, insider David Davidson sold 6,000 shares of the firm’s stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $180.30, for a total value of $1,081,800.00. Following the sale, the insider now directly owns 21,977 shares of the company’s stock, valued at $3,962,453.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Nick Leschly sold 5,435 shares of the firm’s stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $173.38, for a total value of $942,320.30. Following the completion of the sale, the chief executive officer now directly owns 171,009 shares in the company, valued at $29,649,540.42. The disclosure for this sale can be found here. Over the last three months, insiders have sold 222,268 shares of company stock worth $38,896,707. 3.90% of the stock is currently owned by insiders.
WARNING: “bluebird bio, Inc. (BLUE) Shares Sold by Cornerstone Capital Management Holdings LLC.” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/11/cornerstone-capital-management-holdings-llc-has-2-31-million-holdings-in-bluebird-bio-inc-blue.html.
bluebird bio Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.